Increased expression of the proto-oncogene, c-myc, in human neuroblastoma cells by reversible inhibition of cell growth.
Expression of the proto-oncogenes N-myc and c-myc in the human neuroblastoma cell line, IMR32, was examined after reversible inhibition of DNA synthesis by treatment with deferoxamine. After 48 h treatment with 10(-5) M deferoxamine, the number of c-myc expressing cells doubled, while N-myc expressing cells did not change. The expression level of c-myc in each cell also increased. These results suggested that the synthesis of cellular factor(s) involved in the degradation of c-myc RNA or its product was suppressed by reversible inhibition of cell growth. The regulatory mechanisms of expression of N-myc and c-myc may be distinct.
Fukuchi
K
K
Department of Clinical Pathology, Showa University School of Medicine, Tokyo, Japan.
Tomoyasu
S
S
Watanabe
K
K
Suzuki
H
H
Kaetsu
T
T
Takagi
Y
Y
Tsuruoka
N
N
Gomi
K
K
D002453:Cell Cycle / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003676:Deferoxamine / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000235:genetics; D016259:Genes, myc; D006801:Humans; D009447:Neuroblastoma / Q000235:genetics* / Q000473:pathology; D000090063:Proto-Oncogene Mas; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D003676:Deferoxamine